Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002345 · ClinicalTrials.gov registry record · Phase 4
The Safety and Effectiveness of Megace in HIV-Infected Women
A Phase 4 study of HIV Infections and Cachexia, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT00002345: Completed Phase 4 study of HIV Infections and Cachexia, sponsored by Bristol-Myers Squibb.
NCT00002345 is a Phase 4 study of HIV Infections and Cachexia that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002345, a Phase 4 study of HIV Infections and Cachexia, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.
Conditions Studied
Interventions
- DRUG Megestrol acetate
Study Locations (4)
California
- Univ of California - Davis Med Ctr / CARES - Sacramento
Connecticut
- Yale Univ Med School - New Haven
District of Columbia
- Georgetown Univ Med Ctr - Washington D.C.
Rhode Island
- Miriam Hosp - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 4 |
What the finished NCT00002345 record still lists
NCT00002345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Megestrol acetate is the first listed.
NCT00002345 reports a single indexed study location in California, Connecticut, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002345 about?
NCT00002345 is a clinical study titled "The Safety and Effectiveness of Megace in HIV-Infected Women". To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.
What is the current status of trial NCT00002345?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants.
What conditions does trial NCT00002345 study?
This clinical trial studies the following conditions: HIV Infections, Cachexia, Anorexia.
What interventions are being tested in trial NCT00002345?
The interventions under investigation include: Megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00002345?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002345 being conducted?
This trial has 4 study locations across California, Connecticut, District of Columbia, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002345's enrollment target sits among peer trials
40 390th of 542 higher than 139 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models